{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Xevinapant", "query": { "intervention": "Xevinapant" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 5, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T04:00:11.384Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04459715", "title": "A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Xevinapant (Debio 1143)", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Intensity Modulation Radiation Therapy (IMRT)", "type": "RADIATION" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 730, "start_date": "2020-08-07", "completion_date": "2024-09-18", "has_results": true, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-09-04T04:00:11.384Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04459715" }, { "nct_id": "NCT06145412", "title": "A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Xevinapan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "External beam", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2023-11-16", "completion_date": "2026-08-04", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-04T04:00:11.384Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "East White Plains", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06145412" }, { "nct_id": "NCT06110195", "title": "Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Neoplasms", "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Xevinapant", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2024-01-24", "completion_date": "2025-05-12", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-09-04T04:00:11.384Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06110195" }, { "nct_id": "NCT06056310", "title": "Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Xevinapant", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "intensity-modulated radiation therapy (IMRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2024-01-18", "completion_date": "2024-08-20", "has_results": true, "last_update_posted_date": "2025-09-29", "last_synced_at": "2026-09-04T04:00:11.384Z", "location_count": 5, "location_summary": "Miami Beach, Florida • Detroit, Michigan • The Bronx, New York + 2 more", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06056310" }, { "nct_id": "NCT05386550", "title": "Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Xevinapant", "type": "DRUG" }, { "name": "IMRT", "type": "RADIATION" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 166, "start_date": "2022-10-06", "completion_date": "2024-08-27", "has_results": true, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-09-04T04:00:11.384Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05386550" } ] }